As of 9:30 AM on the 6th, Seegene is trading at 278,900 KRW, down 0.32% from the previous day. The trading volume is 341,625 shares, which is about 21.3% of the previous day's volume. Seegene is known as a developer, manufacturer, and seller of molecular diagnostic reagents.


On September 29, researcher Dalmi Lee from SK Securities forecasted that "the company's performance growth is expected to continue until next year. First, in preparation for the colder weather, the export approval for a diagnostic kit capable of simultaneously diagnosing seasonal flu and COVID-19 was obtained this month and is scheduled to be launched soon. Additionally, with an increase in equipment sales, performance improvements are expected not only for COVID-19 but also for other respiratory diagnostic kits, so the growth trend is expected to continue through 2021." Lee set Seegene's target price at 330,000 KRW.


Over the past five days, individual investors have net sold 260,294 shares of Seegene, while foreigners and institutions have net bought 206,953 shares and 65,320 shares respectively.



※ Source: AI Investment Assistant AI Rassiro


※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing